Literature DB >> 30968291

Diffractive trifocal pseudophakic intraocular lenses in high myopic eyes: 2-year assessment after implantation.

Jaime Javaloy1, Ester Rivera2, Raúl Montalbán3, Jaime Beltrán4, Gonzalo Muñoz5, Stephanie Rohrweck5.   

Abstract

PURPOSE: To assess the visual outcomes and ocular safety when implanting diffractive trifocal intraocular lenses in a population of high myopic eyes.
METHODS: This is a retrospective cumulative clinical study. Two hundred five myopic eyes consecutively operated in the hospitals of Clínica Baviera, Spain, were included. All eyes presented an axial length equal or greater than 26 mm and were treated and examined following the same methodology for at least 2 years. Refractive and visual outcomes and also intraoperative or postoperative complications were tabulated for later analysis. Furthermore, a subjective questionnaire was completed by all patients at the end of the follow-up period.
RESULTS: The percentage of eyes that lost two or more lines of corrected distance visual acuity (CDVA) was 5.9%, 11.5% and 10.7% 3, 12 and 48 months after surgeries respectively. However, 33% of eyes gained two or more lines of CDVA 2 years after implantation. Excimer laser correction of residual refractive error was performed after implants in 29.75% of eyes. Uncorrected distance visual acuities (UDVAs) were significantly better 1 year (0.10 ± 0.3 logMAR) and 2 years after the surgeries (0.10 ± 0.14 logMAR) compared with those estimated 3 months postoperatively (0.14 ± 0.15 logMAR; Kruskal-Wallis; p < 0.001). Mean near and intermediate uncorrected visual acuities remained stable from the first to the last postoperative visit (Kruskal-Wallis; p > 0.05 for all comparisons). Of the eyes, 27.31% were diagnosed and treated with yttrium aluminum garnet (YAG) laser after being diagnosed as having posterior capsular opacification. Retinal detachment (RD) was diagnosed in six eyes (2.92%).
CONCLUSIONS: Diffractive trifocal IOLs have good efficacy and predictability in high myopic eyes. Retinal concerns should lead the surgeons to explore other alternatives for refractive surgery in young patients without cataracts.

Entities:  

Keywords:  Cataract surgery; Diffractive IOL; High myopia; Lens surgery; Trifocal IOL

Mesh:

Year:  2019        PMID: 30968291     DOI: 10.1007/s00417-019-04302-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  5 in total

1.  Retinal detachment after phacoemulsification in refractive surgery clinics: a large series analysis with variable follow-up during 16 years.

Authors:  Jaime Javaloy; Vasyl Druchkiv; Jaime Beltrán; Jaime Moya; César Albarrán-Diego; Raúl Montalbán; Gonzalo Muñoz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-03-31       Impact factor: 3.117

2.  Comparison of visual outcomes of a diffractive trifocal intraocular lens and a refractive bifocal intraocular lens in eyes with axial myopia: a prospective cohort study.

Authors:  Tong Sun; Yiyun Liu; Yufei Gao; Chuhao Tang; Qianqian Lan; Tingting Yang; Xiaorui Zhao; Hong Qi
Journal:  BMC Ophthalmol       Date:  2022-10-20       Impact factor: 2.086

3.  Nd:YAG Capsulotomy Rates with Two Multifocal Intraocular Lenses.

Authors:  Huiran Bai; Honglei Li; Simeng Zheng; Lihong Sun; Xiaoming Wu
Journal:  Int J Gen Med       Date:  2021-11-30

4.  Visual performance, safety and patient satisfaction after bilateral implantation of a trifocal intraocular lens in presbyopic patients without cataract.

Authors:  Joaquín Fernández; José F Alfonso Sánchez; Mark Nieradzik; Beatriz Valcárcel; Noemí Burguera; Alexander Kapp
Journal:  BMC Ophthalmol       Date:  2022-08-10       Impact factor: 2.086

5.  Presbyopia-correcting performance and subjective outcomes of a trifocal intraocular lens in eyes with different axial lengths: A prospective cohort study.

Authors:  Tong Sun; Yiyun Liu; Xiaorui Zhao; Yufei Gao; Tingting Yang; Qianqian Lan; Chuhao Tang; Hong Qi
Journal:  Front Med (Lausanne)       Date:  2022-09-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.